Claybrook Capital’s AstraZeneca AZN Stock Holding History

Claybrook Capital’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-35	Closed	-$3K	–	140
2018 Q4	$3K	Buy	+35	New	+$2.73K	﹤0.01%	608

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Claybrook Capital's AZN Position: Q1 2019 in Review

Claybrook Capital sold out of AstraZeneca (AZN) in Q1 2019, closing a stake of 35 shares — an estimated $3K sold.

Claybrook Capital first reported a position in AZN in Q4 2018 and held it in 1 quarter. The position peaked at $3K in Q4 2018. 559 funds tracked by Wall St. Rank hold AZN as of Q1 2019.

Claybrook Capital reported no remaining AstraZeneca position as of Q1 2019 after selling out during the quarter.
Claybrook Capital sold 35 AstraZeneca shares in Q1 2019, an estimated $3K.
Claybrook Capital first reported a position in AstraZeneca in Q4 2018 and held it in 1 quarter.
Claybrook Capital's AstraZeneca position peaked at $3K in Q4 2018.
559 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2019.

Based on Claybrook Capital's 13F filing for Q1 2019, filed 15 May 2019.